Core Viewpoint - The recent announcement by Vaili Zhibo has not garnered significant market attention despite the potential of its core product reaching key R&D milestones, which typically attracts investor interest in the Hong Kong stock market for unprofitable 18A companies [3][4]. Market Reaction - Following the announcement, Vaili Zhibo's stock price rose by 3.15% and 1.44% on January 15 and 16, respectively, but subsequently experienced a "three consecutive declines" trend, influenced by the overall pullback in the Hong Kong medical sector and the upcoming cornerstone lock-up expiration [3][4]. - The Hang Seng Healthcare Index reached a peak of 4326.18 points on January 15 before entering a "four consecutive down" trend, indicating a market correction after a period of gains [4]. Trading Volume and Technical Analysis - Vaili Zhibo experienced a "seven consecutive up" trend from December 30 to January 8, coinciding with the company's participation in the JPM conference, but this rally lacked substantial trading volume support, indicating a potential "false breakout" in technical terms [6][8]. - The daily trading volume peaked at 224.58 million shares at the start of the rally but subsequently declined, suggesting a lack of market support and leading to a downward price trend [6]. Cornerstone Lock-up Expiration - Vaili Zhibo's cornerstone investors, who collectively subscribed for $69 million (approximately 542 million HKD) during the IPO, will face a lock-up expiration on January 25, 2025, which could lead to profit-taking and market pressure [8][10]. - As of January 21, the stock price was 51.25 HKD, indicating that cornerstone investors have an approximate 50% unrealized gain, providing them with a favorable exit opportunity [8]. Future Market Dynamics - The upcoming inclusion of Vaili Zhibo in the Hong Kong Stock Connect program in March 2025, with an average market capitalization of 9.462 billion HKD, positions it as a potential target for new capital inflows [10][12]. - The behavior of cornerstone investors during the lock-up expiration will serve as a critical indicator for market sentiment and could influence the stock's performance in the context of new capital entering the market [10][14]. Company Fundamentals - Vaili Zhibo's innovative strategy focuses on T cell connectors, tumor immunology 2.0, and antibody-drug conjugates, with its core product LBL-024 being a significant asset in its pipeline [13][14]. - LBL-024 has received fast track designation from the FDA for treating neuroendocrine cancer, highlighting its potential and the recognition from regulatory bodies [13].

Core Viewpoint - The recent announcement by Vaili Zhibo has not garnered significant market attention despite the potential of its core product reaching key R&D milestones, leading to a decline in stock price after initial gains [3][5]. Market Reaction - Following the announcement on January 15, Vaili Zhibo's stock rose by 3.15% and 1.44% on January 15 and 16, respectively, but subsequently faced a "three consecutive drop" trend [3]. - The decline in stock price is attributed to a broader pullback in the Hong Kong pharmaceutical sector, with the Hang Seng Healthcare Index experiencing a "four consecutive drop" from January 15 to 20 [3]. - Investor sentiment has shifted to a wait-and-see approach due to the upcoming performance forecasts from multiple pharmaceutical companies for the year 2025 [3]. Technical Analysis - Vaili Zhibo experienced a "seven consecutive rise" from December 30 to January 8, aligning with the overall upward trend in the Hong Kong pharmaceutical sector, driven by expectations from the JPM conference [5]. - Despite the initial rise, the lack of increased trading volume indicated a weak market support, leading to a subsequent decline in stock price [5][7]. Upcoming Events - Vaili Zhibo is set to face a cornerstone lock-up expiration on January 25, which could impact market dynamics as cornerstone investors hold significant unrealized gains [7]. - The cornerstone investors, who collectively subscribed to approximately $69 million (about 542 million HKD) of shares, represent 50.74% of the total offering [7]. Investment Considerations - The average market capitalization of Vaili Zhibo during the review period was 9.462 billion HKD, surpassing the 9.247 billion HKD threshold for inclusion in the Hong Kong Stock Connect, indicating potential for increased foreign investment [9][11]. - The performance of cornerstone investors post-lock-up expiration may serve as a critical indicator for market sentiment and investment decisions by new capital inflows [9][13]. Product Pipeline - Vaili Zhibo's innovative strategy focuses on T cell connectors, tumor immunology 2.0, and antibody-drug conjugates, with LBL-024 being a key product in the IO2.0 field [12]. - LBL-024 has received fast track designation from the FDA for treating neuroendocrine carcinoma, highlighting its potential in the oncology market [12].

Core Insights - The article discusses the IPO progress of Aimi Biotech, a pioneer in next-generation bispecific antibodies, focusing on its innovative T cell engagers (TCE) for cancer and autoimmune disease treatment [1][2]. Group 1: Company Overview - Aimi Biotech is at the forefront of the bispecific antibody treatment field, aiming to develop TCEs globally for various cancers and autoimmune diseases [1]. - The company plans to use the net proceeds from the IPO primarily for clinical development of core products, pipeline expansion, and operational funding [1]. - Aimi Biotech has a strong leadership team with extensive industry experience, including founder Dr. Wu Chenbing and Chief Medical Officer Dr. Zhu Yonghong, which supports its strategic execution and technology transfer [2]. Group 2: Technology and Product Pipeline - Aimi Biotech has developed proprietary technology platforms, including FIT-Ig, MAT-Fab, and a CD3 antibody library, which are crucial for advancing bispecific antibody development [2][3]. - The FIT-Ig platform is unique as it does not require amino acid mutations or linker peptides, with clinical projects like EMB-01 and EMB-06 already in advanced stages [3]. - The company has established seven product pipelines covering oncology and immunology, including key products EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [2]. Group 3: Market Potential and Collaborations - The global bispecific antibody market is projected to reach $221.8 billion by 2034, with a compound annual growth rate (CAGR) of 32.4% from 2024 to 2034 [1]. - Aimi Biotech has secured multiple licensing agreements since the end of 2023, with a total transaction value exceeding $2.1 billion, ranking second globally in the TCE field [4]. - The company is positioned to accelerate the commercialization of innovative drugs, enhancing its competitive edge in the rapidly growing bispecific antibody and TCE treatment markets [4].